TNK Therapeutics is a fully owned subsidiary of Sorrento Therapeutics, Inc. and utilizes Sorrentos G-MAB library to create novel chimeric antigen receptor (CAR) constructs for the generation of CAR.TNKs and other cellular therapies.
TNK Therapeutics, Inc.
In Dec 2014, Sorrento entered into a global exclusive partnership with Conkwest, Inc., to codevelop CAR.TNK based cancer and infectious therapeutics. Presently, TNK Therapeutics is responsible for this colla.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
The CAR.TNK technology platform combines Conkwests Neukoplast cell line with Sorrentos proprietary G-MAB_ fully human antibody technology and CAR designs to further enhance the anti-cancer potency and tumor targeting of Neukoplast.
In Aug 2015, TNK Therapeutics, acquired multiple preclinical and clinical stage chimeric antigen receptor (CAR)-T immunotherapy programs as well as underlying CAR-T technology through the acquisition of two undisclosed privately-held biotechnology companies.
In Nov 2016, TNK Therapeutics acquired Virttu Biologics, based at Glasgow, Scotland, developing oncolytic virus therapy for treatment of cancer. Virttus lead product candidate Seprehvirë (HSV1716) is a Herpes Simplex Virus (HSV)-based oncolytic virus that selectively kills cancer cells and eliciting an anti-tumor immune response in the patient.